Резултати

eNauka >  Results >  Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Title: Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Authors: Robinson, Michael F; Damjanov, Nemanja S; Stamenkovic, Bojana N  ; Radunovic, Goran L  ; Kivitz, Alan J; Cox, Lori; Manukyan, Zorayr; Banfield, Christopher; Saunders, Michael; Chandra, Deepa;
Vincent, Michael S; Mancuso, Jessica; Peeva, Elena; Beebe, Jean S;
Issue Date: 2020
Publication: ARTHRITIS & RHEUMATOLOGY
ISSN: 2326-5191 Arthritis & Rheumatology Search Idenfier
Type: Article
Collation: vol. 72 br. 10 str. 1621-1631
DOI: 10.1002/art.41316
WoS-ID: 000566537900001
Scopus-ID: 2-s2.0-85090310586
PMID: 32419304
PMCID: PMC7589242
URI: https://enauka.gov.rs/handle/123456789/800099
Project: Pfizer, Inc.Pfizer
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
21aM21a

75
SCOPUSTM
31
PubMed CentralTM
30
OpenCitations
68
WEB OF SCIENCETM
Алт метрика
Dimensions
Unpaywall

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.